7. C reactive Protein (CRP) level greater than 30 mg/L within the 4 weeks prior to study drug administration.
8. Uncontrolled or symptomatic secondary hyperparathyroidism，iPTH\>500pg/ml.
9. Poorly controlled hypertension within 2 weeks prior to study drug administration, per investigator's clinical judgment (e.g. systolic ≥ 160mm Hg, diastolic ≥ 100 mm Hg).
10. Chronic congestive heart failure (New York Heart Association Class IV).
11. Significant symptom within 6 months prior to study drug administration (e.g. myocardial infarction, serious or precarious coronary artery disease,stroke, respiratory disease, autoimmune disease, neuropathy, phrenopathy, hepatopathy including Active hepatitis B, Active hepatitis C, or ALT\> 2 x upper limit of normal (ULN), AsT\> 2 x upper limit of normal (ULN) , etc.).
12. A positive test for HIV antibody.
13. Tumor malignancy
14. Expected survival less than 12 months,
15. A scheduled kidney transplant
16. Major surgery (may Massive bleeding) during the study
17. Expected conception within 4 Weeks after the end of the Study Treatment
18. The subject has participated in other clinical trial within the 6 weeks prior to study drug administration
19. Have any other condition or prior therapy that, in the investigator's opinion, would make the subject unsuitable for the study, or unable or unwilling to comply with the study procedures.
